LambdaTest Partners with LinkedIn to Offer Test Automation Professional Certificate on LinkedIn Learning
6.3.2023 19:00:00 EET | Business Wire | Press release
LambdaTest, the leading digital experience testing cloud platform, has partnered with LinkedIn to offer the LambdaTest Test Automation Professional Certificate exclusively available on LinkedIn Learning, as part of its mission to support the testing and QA community.
Through this Professional Certificate course, learners will acquire fundamental knowledge of test automation, including various tools and best practices, in a highly engaging manner from Meaghan Lewis, Technical Program Manager at Microsoft.
More importantly, learners will be able to implement and optimize test automation in their jobs after this course. To earn their LambdaTest Test Automation Professional Certificate, learners will have to complete all courses and content in the learning path and pass the final exam. Learners can access their certificates immediately after they pass the final exam and seamlessly showcase their certificate on LinkedIn.
"We are excited to partner with LambdaTest to provide our customers and learners additional, credible paths to upskilling as well as broaden the audience for the LambdaTest Test Automation Professional Certificate to the world’s largest talent marketplace," said Dan Brodnitz, Sr. Director of Global Content Strategy at LinkedIn Learning.
As LinkedIn Learning students for the LambdaTest Test Automation Professional Certificate, learners can get free trial access to the LambdaTest platform. This enables learners to get hands-on experience and implement the concepts.
“Enterprises, all over the world, are automating their testing to ensure a better digital experience for their users. Learning test automation will open up various career avenues for learners. We are also happy to offer free access to the LambdaTest platform to enable students to get hands-on experience. We are excited to play our role in enabling thousands of learners to achieve their career goals,” said Maneesh Sharma, Chief Operating Officer, LambdaTest.
LambdaTest recently announced the launch of digital experience testing cloud for enterprises. The offering will enable enterprises to accelerate their digital transformation by providing a best-in-class, 360-degree test execution and orchestration platform coupled with insightful test analytics and customizable deployment options.
Also, Satya Nadella, Chairman & CEO of Microsoft, delivered the keynote address at the Microsoft Future Ready Technology Summit 2023, Bengaluru, where he said that “LambdaTest is doing for test automation what Kubernetes did for container orchestration - creating that next level of efficiency around test automation so that people can actually focus on testing versus test orchestration.”
To know more, visit: https://www.lambdatest.com/certifications/linkedin-learning
Notes to the editor
For further information please contact the LambdaTest press office: press@lambdatest.com.
About LambdaTest
LambdaTest is a leading digital experience testing cloud that helps developers and testers ship code faster. Over 10,000+ enterprise customers and 2+ million users across 130+ countries rely on LambdaTest for their testing needs.
LambdaTest platform provides secure, scalable, and insightful test orchestration for customers at different points in their DevOps (CI/CD) lifecycle:
● Cross Browser Testing Cloud
LambdaTest test execution platform allows users to run both manual and automated tests across 3000+ different browsers, real devices, and operating system environments. It enables developers to test their websites, web applications, and native apps without requiring to install or maintain an internal lab of virtual machines, real devices, emulators, or simulators.
● Real Device Testing Cloud
With LambdaTest’s Real Devices Testing Cloud, you can now test unhandled errors, UI/UX, performance, and functionality of your native, web, and hybrid apps before they get released into production. Test on the widest range of mobile and OTT devices (iOS, Android, iPad, Amazon Fire TV, Roku TV & Apple TV). With seamless cross-functional team collaboration across the mobile app development lifecycle, you can release quality mobile apps in shorter development cycles which enables you to innovate and scale rapidly.
● Continuous Testing Cloud - HyperExecute
An IP-led next-gen cloud test execution and orchestration platform that helps enterprises run end-to-end automation tests at the fastest speed possible, thereby enabling them to achieve quicker time-to-market, and deliver a quality digital experience. Achieve 70% faster test execution times and zero flakiness with HyperExecute.
● Visual Regression cloud
Perform Regression Testing in just one click using LambdaTest. Compare the screenshots of your application’s webpages taken from two different browsers to view/detect any visual deviations. Increase browser coverage by running automation scripts on a cloud of 3000+ different desktop and mobile environments.
● Test Intelligence at Scale
Test execution insights are critical for digital transformation as they provide enterprises with more profound insight into the quality of releases and trends. By analyzing the test execution data, LambdaTest's Integrated Test Intelligence delivers enterprises with insights into patterns and trends that can lead to informed decisions about future development and improve application quality.
For more information, please visit: https://lambdatest.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230306005067/en/
Contact information
LambdaTest press office:
press@lambdatest.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 10:00:00 EEST | Press release
Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 years, she has led global teams to achieve a 100% success rate from Phase 3 development through to FDA approval for multiple programs spanning oncology, immunology and respiratory medicine. In addition, she raised funds of around $400M as founder and CEO. Across her career she has contributed to 20 drug approvals, engaging
TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 10:00:00 EEST | Press release
Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network upgrades. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260803353435/en/ Adtran’s SDX 6400 Series is helping TOHKnet demonstrate how Japan’s operators can migrate to 50G PON without disrupting existing PON services. “As demand for digital services continues to grow, this trial is a key milestone for the future of fiber access in Jap
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 10:00:00 EEST | Press release
The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the project continues to captivate audiences through its
Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer4.8.2026 10:00:00 EEST | Press release
Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer. Rupitasertib, is a first-in-class oral dual-node PI3K/AKT/mTOR (PAM) pathway inhibitor, which selectively inhibits S6K and AKT1/3. Rupitasertib was purposefully and rationally designed to target S6K for potent PAM inhibition and AKT1/3 to block the AKT compensatory feedback loop, while sparing AKT2 to avoid hyperglycemia, which we believe will lead to a superior efficacy and safety profile compared to other PAM pathway inhibitors. Under the terms of the agreement, Roche will s
Bending Spoons has entered into a definitive agreement to acquire Airtable for $1.285 billion4.8.2026 09:30:00 EEST | Press release
Bending Spoons S.p.A. (NASDAQ: BSP) announced that it has entered into a definitive agreement to acquire Airtable, in an all-cash transaction that values Airtable at an enterprise value of $1.285 billion, which, together with Airtable’s current net cash-and-cash-equivalents balance, implies an equity value of approximately $2.25 billion. The acquisition is subject to customary closing conditions and approvals, including regulatory approvals. “We’re looking forward to welcoming Airtable into Bending Spoons,” said Luca Ferrari, Bending Spoons CEO and co-founder. “Airtable is a pioneering brand reshaping how teams organize data and manage critical workflows. The value being delivered is reflected in annual recurring revenue growing over 20% YoY to approximately $480 million as of June 2026, and joining forces with Bending Spoons will accelerate innovation even further. We’re committed to investing in Airtable for the long run, and doubling down on its core strength: bringing teams and wor
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom